Meridian Bioscience (Nasdaq: VIVO ) is expected to report Q1 earnings around Jan. 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Meridian Bioscience's revenues will grow 10.4% and EPS will expand 11.8%.
The average estimate for revenue is $44.4 million. On the bottom line, the average EPS estimate is $0.19.
Last quarter, Meridian Bioscience logged revenue of $43.7 million. GAAP reported sales were 5.7% higher than the prior-year quarter's $41.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.21. GAAP EPS of $0.20 for Q4 were 25% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 63.5%, 160 basis points better than the prior-year quarter. Operating margin was 27.6%, 20 basis points worse than the prior-year quarter. Net margin was 19.6%, 340 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $189.4 million. The average EPS estimate is $0.87.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 475 rating the stock outperform, and 12 members rating it underperform. Among 117 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 115 give Meridian Bioscience a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $17.00.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Meridian Bioscience. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.